Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients’ heart?

References

• Malet-MartinoMJolimaitrePMartinoRThe prodrugs of 5-fluorouracilCurr Med Chem Anticancer Agents20022226731012678747
   PubMedGoogle Scholar
• AprileGMazzerMMorosoSPuglisiFPharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancerAnticancer Drugs200920421722919247178
   PubMed Web of Science ®Google Scholar
• MikhailSESunJFMarshallJLSafety of capecitabine: a reviewExpert Opin Drug Saf20109583184120722491
   PubMed Web of Science ®Google Scholar
• AlbiniAPennesiGDonatelliFCammarotaRDe FloraSNoonanDMCardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological preventionJ Natl Cancer Inst20101021142520007921
   PubMedGoogle Scholar
• PolkAVaage-NilsenMVistisenKNielsenDLCardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factorsCancer Treat Rev201339897498423582737
   PubMed Web of Science ®Google Scholar
• SingletarySEConnollyJLBreast cancer staging: working with the sixth edition of the AJCC Cancer Staging ManualCA Cancer J Clin20065613747 quiz 50–5116449185
   PubMed Web of Science ®Google Scholar
• ZambettiMMansuttiMGomezPPathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)Breast Cancer Res Treat2012132384385121750964
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med2006355262733274317192538
   PubMed Web of Science ®Google Scholar
• ImazioMTrincheroRMyopericarditis: Etiology, management, and prognosisInt J Cardiol20081271172618221804
   PubMed Web of Science ®Google Scholar
• GianniMDentaliFLonnE5 flourouracil-induced apical ballooning syndrome: a case reportBlood Coagul Fibrinolysis200920430630819300240
   PubMed Web of Science ®Google Scholar
• KobayashiNHataNYokoyamaSShinadaTShirakabeAMizunoKA case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinomaJ Nippon Med Sch2009761273319305108
   PubMedGoogle Scholar
• StewartTPavlakisNWardMCardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic anginaIntern Med J201040430330720529041
   PubMed Web of Science ®Google Scholar
• Y-HassanSTornvallPTörnerudMHenarehLCapecitabine caused cardiogenic shock through induction of global Takotsubo syndromeCardiovasc Revasc Med2013141576123218901
   PubMedGoogle Scholar
• KurowskiVKaiserAvon HofKApical and midventricular transient left ventricular dysfunction syndrome (tako-tsubo cardiomyopathy): frequency, mechanisms, and prognosisChest2007132380981617573507
   PubMed Web of Science ®Google Scholar
• SimmonsAVacekJLMeyersDAnthracycline-induced cardiomyopathyPostgrad Med20081204677219020367
   PubMed Web of Science ®Google Scholar
• FerransVJClarkJRZhangJYuZXHermanEHPathogenesis and prevention of doxorubicin cardiomyopathyTsitologiia199739109289379505340
   PubMedGoogle Scholar
• CamaroCDansePWBoskerHAAcute chest pain in a patient treated with capecitabineNeth Heart J2009177–828829119789697
   PubMed Web of Science ®Google Scholar
• KusamaYKodaniENakagomiAVariant angina and coronary artery spasm: the clinical spectrum, pathophysiology, and managementJ Nippon Med Sch201178141221389642
   PubMed Web of Science ®Google Scholar
• SüdhoffTEnderleMDPahlkeM5–Fluorouracil induces arterial vasocontractionsAnn Oncol200415466166415033676
   PubMed Web of Science ®Google Scholar
• GoldsmithYBRoistacherNBaumMSCapecitabine-induced coronary vasospasmJ Clin Oncol200826223802380418669470
   PubMed Web of Science ®Google Scholar
• GoliasCDimitriadisGDimitriadisDAcute presentation of vasospastic angina induced by oral capecitabine: a case reportJ Med Case Rep201481824428956
   PubMedGoogle Scholar
• KuppensIEBootHBeijnenJHSchellensJHLabadieJCapecitabine induces severe angina-like chest painAnn Intern Med2004140649449515023730
   PubMed Web of Science ®Google Scholar
• ShahNRShahARatherAVentricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasmJ Oncol Pharm Pract201218113213521321041
   PubMedGoogle Scholar
• FradleyMGBarrettCDClarkJRFrancisSAVentricular fibrillation cardiac arrest due to 5-fluorouracil cardiotoxicityTex Heart Inst J201340447247624082383
   PubMed Web of Science ®Google Scholar
• WangKAsingerRWMarriottHJST-segment elevation in conditions other than acute myocardial infarctionN Engl J Med2003349222128213514645641
   PubMed Web of Science ®Google Scholar
• LestuzziCTartuferiLCoronaGCapecitabine (and 5 fluorouracil) cardiotoxicity. Metabolic considerationsBreast J2011175564565 author reply 566–56721726348
   PubMed Web of Science ®Google Scholar
• LambertiMPortoSZappavignaSA mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectivesToxicol Lett2014227315115624704391
   PubMed Web of Science ®Google Scholar
• Van CutsemEHoffPMBlumJLAbtMOsterwalderBIncidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracilAnn Oncol200213348448511996484
   PubMed Web of Science ®Google Scholar
• KosmasCKallistratosMSKopteridesPCardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective studyJ Cancer Res Clin Oncol20081341758217636329
   PubMed Web of Science ®Google Scholar
• LestuzziCVielEPicanoEMeneguzzoNCoronary vasospasm as a cause of effort-related myocardial ischemia during low-dose chronic continuous infusion of 5-fluorouracilAm J Med2001111431631811566462
   PubMed Web of Science ®Google Scholar
• MiuraKKinouchiMIshidaK5-fu metabolism in cancer and orally-administrable 5-fu drugsCancers (Basel)2010231717173024281184
   PubMedGoogle Scholar
• MosseriMFingertHJVarticovskiLChokshiSIsnerJMIn vitro evidence that myocardial ischemia resulting from 5- fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscleCancer Res19935313302830338391384
   PubMed Web of Science ®Google Scholar
• ShoemakerLKAroraURocha LimaCM5-fluorouracil-induced coronary vasospasmCancer Control2004111464914749623
   PubMedGoogle Scholar
• EskilssonJAlbertssonMFailure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamilActa Oncol1990298100110032278719
   PubMed Web of Science ®Google Scholar
• PatelBKlonerRAEnsleyJAl-SarrafMKishJWynneJ5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilatorsAm J Med Sci198729442382433661619
   PubMed Web of Science ®Google Scholar
• KinhultSAlbertssonMEskilssonJCwikielMAntithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluationScanning20012311811272331
   PubMed Web of Science ®Google Scholar
• De ForniMMalet-MartinoMCJaillaisPCardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical studyJ Clin Oncol19921011179518011403060
   PubMed Web of Science ®Google Scholar
• JensenSASørensenJBRisk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabineCancer Chemother Pharmacol200658448749316418875
   PubMed Web of Science ®Google Scholar
• MeyerCCCalisKABurkeLBWalawanderCAGraselaTHSymptomatic cardiotoxicity associated with 5-fluorouracilPharmacotherapy19971747297369250550
   PubMed Web of Science ®Google Scholar
• KocaDSalmanTUnekITClinical and electrocardiography changes in patients treated with capecitabineChemotherapy201157538138721997165
   PubMed Web of Science ®Google Scholar
• IgnatescuMCGharehbaghi-SchnellEHassanAExpression of the angiogenic protein, platelet-derived endothelial cell growth factor, in coronary atherosclerotic plaques: In vivo correlation of lesional microvessel density and constrictive vascular remodelingArterioscler Thromb Vasc Biol199919102340234710521362
   PubMed Web of Science ®Google Scholar
• LestuzziCVaccherETalaminiREffort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated riskAnn Oncol20142551059106424558023
   PubMed Web of Science ®Google Scholar
• NgMCunninghamDNormanARThe frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)Eur J Cancer200541111542154615978800
   PubMed Web of Science ®Google Scholar
• OztopIGencerMOkanTEvaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancersJpn J Clin Oncol200434526226815231861
   PubMed Web of Science ®Google Scholar
• SalepciTSekerMUyarelH5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levelsMed Oncol201027241642019415535
   PubMed Web of Science ®Google Scholar
• HolubecLJrTopolcanOFinekJDynamic monitoring of cardio-specific markers and markers of thyroid gland function in cancer patients – a pilot studyAnticancer Res2007274A1883188617649788
   PubMed Web of Science ®Google Scholar
• CeyhanCMeydanNBarutcaSUltrasound tissue characterization by integrated backscatter for analyzing Fluorouracil induced myocardial damageEchocardiography200522323323815725158
   PubMed Web of Science ®Google Scholar
• CianciGMorelliMFCannitaKProphylactic options in patients with 5-fluorouracil-associated cardiotoxicityBr J Cancer200388101507150912771913
   PubMed Web of Science ®Google Scholar
• LabiancaRLuporiniG5-fluorouracil cardiotoxicity: the risk of rechallengeAnn Oncol1991253831954185
   PubMed Web of Science ®Google Scholar